Piotr Wnuk, Author at

The first-in class medicine for severe asthma co-developed by AstraZeneca and Amgen is poised for accelerated approval after

Breakthrough designation AstraZeneca’s severe asthma drug

https://pharmaphorum.com/news/astrazeneca-asthma-breakthrough/

Digital/ News/ News

SBRI Healthcare digital projects saved NHS £30 million so far

Piotr Wnuk digital healthcare, digital NHS, NHS England, SBRI Healthcare 0 Comment

An NHS England technology funding enterprise, the Small Business Research Initiative (SBRI) Healthcare, secured over £30 million in

SBRI Healthcare digital projects saved NHS £30 million so far

https://pharmaphorum.com/digital/sbri-digital-projects-saved-nhs-30m/

GlaxoSmithKline/ News/ Top stories/ US

GSK cuts 650 jobs in the US

Piotr Wnuk GlaxoSmithKline 0 Comment

GlaxoSmithKline moves ahead with its planed cost saving strategy and cuts 650 jobs in North Carolina, according to

GSK cuts 650 jobs in the US

https://pharmaphorum.com/news/glaxosmithkline-cuts-650-jobs/

News/ Novartis/ Top stories/ US

Novartis sells parts of Sandoz for $1bn

Piotr Wnuk 5, Novartis, Sandoz 0 Comment

After disappointing sales, Novartis trades in the Sandoz US dermatology business and generic oral solids portfolio to Aurobindo

Novartis sells parts of Sandoz for $1bn

https://pharmaphorum.com/news/novartis-sells-sandoz-parts/

News

Sanofi to pay $25 million in bribery charges settlement

Piotr Wnuk Bribery, Sanofi 0 Comment

French pharma giant Sanofi reached a civil settlement with the US Securities and Exchange Commission (SEC) and agreed

Sanofi to pay $25 million in bribery charges settlement

https://pharmaphorum.com/news/sanofi-pays-25-m-bribery-settlement/

Cancer/ News/ News/ News/ Oncology/ R&D

Puma Biotechnology’s breast cancer drug approved in Europe

Piotr Wnuk breast cancer, HER2-positive breast cancer, Puma Biotechnology 0 Comment

Puma Biotechnology received European Commission (EC) marketing authorisation for Nerlynx (neratinib) in breast cancer, despite earlier European Medicines

Puma Biotechnology’s breast cancer drug approved in Europe

https://pharmaphorum.com/news/ec-approves-puma-breast-cancer-drug/

News/ News/ R&D

Abivax sets its course on colitis and Crohn’s

Piotr Wnuk Abivax, Crohn's disease, ulcerative colitis 0 Comment

French biotech moves on with the late stage drug development, after publishing impressive clinical trial results of ABX464

Abivax sets its course on colitis and Crohn’s

https://pharmaphorum.com/news/abivax-scolitis-crohns/

Brexit/ Market Access/ UK & Europe/ Views & Analysis/ Views and analysis

UK’s drug supply contingency plan for hard Brexit

Piotr Wnuk Brexit, Brexit contingency plan, Brexit Health Alliance, Matt Hancock, no-deal Brexit 0 Comment

The UK government has issued several documents to help businesses in planning for the eventuality of a no-deal

UK’s drug supply contingency plan for hard Brexit

https://pharmaphorum.com/views-analysis-market-access/hard-brexit-uk-drug-supply-contingency-plan/

News/ UK & Europe

Ipsen appoints new general manager for the UK & Ireland

Piotr Wnuk appointments, Ipsen 0 Comment

The French pharma company appointed a new general manager for its UK and Ireland office, Asad Mohsin Ali,

Ipsen appoints new general manager for the UK & Ireland

https://pharmaphorum.com/news/ipsen-appoints-new-general-manager/

Trending

About Piotr Wnuk

Posts by Piotr Wnuk:

Breakthrough designation AstraZeneca’s severe asthma drug

SBRI Healthcare digital projects saved NHS £30 million so far

GSK cuts 650 jobs in the US

Novartis sells parts of Sandoz for $1bn

Sanofi to pay $25 million in bribery charges settlement

Puma Biotechnology’s breast cancer drug approved in Europe

Abivax sets its course on colitis and Crohn’s

UK’s drug supply contingency plan for hard Brexit

Ipsen appoints new general manager for the UK & Ireland

Trending

About Piotr Wnuk

Posts by Piotr Wnuk:

Login